Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Pressure is growing for greater disclosure of study results, which may shift industry R&D, Schering compliance VP Saunders says. Former DoJ attorney Bentivoglio suggests that disclosure requirements would include cost-effectiveness data.